News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,598 Results
Type
Article (13937)
Company Profile (300)
Press Release (247361)
Section
Business (79353)
Career Advice (151)
Deals (13189)
Drug Delivery (34)
Drug Development (50325)
Employer Resources (31)
FDA (5681)
Job Trends (5114)
News (144127)
Policy (10018)
Tag
Academia (901)
Alliances (21522)
Alzheimer's disease (755)
Approvals (5658)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4519)
Biotechnology (245)
Breast cancer (109)
Cancer (880)
Cardiovascular disease (71)
Career advice (132)
CAR-T (71)
Cell therapy (213)
Clinical research (40118)
Collaboration (301)
Compensation (127)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (66)
Data (979)
Diabetes (83)
Diagnostics (1207)
Drug discovery (56)
Earnings (29000)
Events (47182)
Executive appointments (240)
FDA (6037)
Funding (301)
Gene editing (63)
Gene therapy (163)
GLP-1 (308)
Government (1064)
Healthcare (6542)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7194)
Job creations (859)
Job search strategy (127)
Layoffs (186)
Legal (1375)
Lung cancer (130)
Lymphoma (60)
Manufacturing (82)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6124)
Metabolic disorders (251)
Neuroscience (998)
NextGen Class of 2024 (2000)
Non-profit (847)
Northern California (1084)
Obesity (137)
Opinion (91)
Parkinson's disease (75)
Patents (60)
People (25090)
Phase I (14142)
Phase II (18654)
Phase III (11814)
Pipeline (364)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1409)
Regulatory (8276)
Research institute (931)
Southern California (970)
Startups (1964)
United States (8576)
Vaccines (164)
Weight loss (80)
Date
Today (79)
Last 7 days (348)
Last 30 days (1525)
Last 365 days (20599)
2024 (20326)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16915)
Australia (2853)
California (2452)
Canada (796)
China (199)
Colorado (90)
Connecticut (103)
Europe (36431)
Florida (271)
Georgia (69)
Illinois (151)
Indiana (61)
Kansas (55)
Maryland (326)
Massachusetts (1939)
Minnesota (99)
New Jersey (620)
New York (675)
North Carolina (416)
Northern California (1084)
Ohio (82)
Pennsylvania (468)
South America (207)
Southern California (970)
Texas (275)
Washington State (245)
261,598 Results for "tallac therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses.
April 10, 2024
·
3 min read
Biotech Bay
Tallac Presents First Clinical Data for TAC-001 at SITC 2023
Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, announced the first presentation of TAC-001 Phase 1 clinical safety and efficacy data in solid tumor patients.
November 3, 2023
·
5 min read
Pharm Country
Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics
Horizon Technology Finance Corporation announced it has provided a $15 million venture loan facility to Tallac Therapeutics, Inc., of which $5 million has been initially funded.
August 2, 2023
·
3 min read
Biotech Bay
Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023.
September 27, 2023
·
3 min read
Business
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
Tallac Therapeutics, Inc. today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.
January 19, 2023
·
4 min read
Biotech Bay
Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
Tallac Therapeutics, Inc. today announced that the Company presented data for two, first-in-class toll-like receptor 9 (TLR9) agonist antibody conjugates from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022).
November 11, 2022
·
5 min read
Business
Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology
Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements
March 23, 2021
·
3 min read
Drug Development
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.
July 28, 2022
·
4 min read
Business
Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer
April 15, 2021
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 26,160
Next
